Roivant to present topline Phase 2 results for mosliciguat in pulmonary hypertension associated with interstitial lung disease at ERS Congress

Roivant and Pulmovant are scheduled to present topline results from their Phase 2 PHocus study of mosliciguat, an inhaled sGC activator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the European Respiratory Society (ERS) International Congress 2026 today. These findings are anticipated to provide important insights into a potential new treatment for this serious condition.